Biogen Inc (BIIB)

333.77 -4.33  -1.28% NASDAQ Aug 5, 09:15 USD
View Full Chart
Price Chart
View All BIIB News

News

View All Events

Events

Date Type Description
10/21/2021 Earnings Results Q3 2021 Earnings Results
10/21/2021 08:00 EST Earnings Calls Q3 2021 Earnings Call
07/22/2021 Earnings Results Q2 2021 Earnings Results
07/22/2021 08:00 EST Earnings Calls Q2 2021 Earnings Call
06/02/2021 AGM 2020 Annual General Meeting
04/22/2021 Earnings Results Q1 2021 Earnings Results
04/22/2021 08:00 EST Earnings Calls Q1 2021 Earnings Call
02/03/2021 Earnings Results Q4 2020 Earnings Results
02/03/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
10/21/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
  • URL: http://www.biogen.com
  • Investor Relations URL: https://investors.biogen.com
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Oct. 21, 2021
  • Last Earnings Release: Jul. 22, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Top Fund Holders

Symbol Name Weighting
LMPFX ClearBridge Aggressive Growth FI 5.70%
PKW Invesco BuyBack Achievers ETF 5.42%
VPMCX Vanguard PRIMECAP Inv 4.22%
BBH VanEck Vectors Biotech ETF 4.08%
IBB iShares Biotechnology ETF 3.74%
VHCOX Vanguard Capital Opportunity Inv 3.45%
FBT First Trust NYSE Arca Biotech ETF 3.32%
VPCCX Vanguard PRIMECAP Core Inv 3.32%
HQH Tekla Healthcare Investors 3.24%
VGHCX Vanguard Health Care Inv 2.48%
MOAT VanEck Vectors Morningstar Wide Moat ETF 2.40%
POAGX PRIMECAP Odyssey Aggressive Growth 2.38%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.